TargetCancer Foundation promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer Foundation directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients. TargetCancer Foundation was founded by Paul Poth in 2009 after his diagnosis with cholangiocarcinoma at age 38. Because his cancer was rare, no treatments existed for it, and very little research was being carried out. Paul passed away in August 2009, but TargetCancer Foundation continues his effort to ensure that others diagnosed with rare cancers will have real treatment options — and a chance to live. By granting seed money to critical research projects that would not otherwise be supported at their initial stages, TargetCancer Foundation supports young, courageous scientists who are committed to finding effective new therapies for rare cancers, and ultimately, all cancers. Since being founded, TargetCancer Foundation has provided over $250,000 in grant funding supporting innovative, high impact research into cholangiocarcinoma and esophageal cancer. In addition, TargetCancer Foundation has funded a fellowship supporting the studies of Harvard Medical School students, and also supported next generation research at the Center for Molecular Therapeutics at Massachusetts General Hospital.